1. Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells
   Sumeet Kaur et al, 2022, Drug Development Research CrossRef
2. Crosstalk of four kinds of cell deaths defines subtypes of cutaneous melanoma for precise immunotherapy and chemotherapy
   Qi Wan et al, 2022, Frontiers in Immunology CrossRef
3. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy
   Yuqing Wen et al, 2024, Cancer Immunology, Immunotherapy CrossRef
4. Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers
   Maria Gracia-Hernandez et al, 2021, Cancers CrossRef
5. HDAC6: A unique HDAC family member as a cancer target
   Sumeet Kaur et al, 2022, Cellular Oncology CrossRef
6. HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells
   Takaaki Oba et al, 2021, Breast Cancer Research and Treatment CrossRef
7. Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
   Jianglei Li et al, 2022, Frontiers in Pharmacology CrossRef
8. The Role of Endoplasmic Reticulum Stress in Melanoma
   Hao-Ze Shi et al, 2023, International Journal of Dermatology and Venereology CrossRef
9. Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways
   Jinlin Cao et al, 2018, Cell Death & Disease CrossRef
10. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways
    Manon Lernoux et al, 2018, Pharmacological Research CrossRef
11. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
    Ilaria Proietti et al, 2020, Cancers CrossRef
12. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises
    I. Anestopoulos et al, 2022, Pharmacology & Therapeutics CrossRef
13. Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor
    Husvinee Sundaramurthi et al, 2022, Cancers CrossRef
14. Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
    Adriana Celesia et al, 2023, International Journal of Molecular Sciences CrossRef
15. Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma
    Koen Vermeulen et al, 2019, Nuclear Medicine and Biology CrossRef
16. LuminoCell: a versatile and affordable platform for real-time monitoring of luciferase-based reporters
    Kamila Weissová et al, 2022, Life Science Alliance CrossRef
17. Curriculum vitae of HDAC6 in solid tumors
    Yi-Chao Zheng et al, 2023, International Journal of Biological Macromolecules CrossRef
18. HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells
    Jung Yoo et al, 2021, Oncology Letters CrossRef
19. Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma
    Husvinee Sundaramurthi et al, 2022, International Journal of Molecular Sciences CrossRef
20. Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models
    Sida Shen et al, 2019, Journal of Medicinal Chemistry CrossRef
21. Histone deacetylase 6 in cancer
    Ting Li et al, 2018, Journal of Hematology & Oncology CrossRef